NCT00461045 · OUTCOME
Duration of MRZ Treatment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- weeks
- Interval / dispersion
- Standard Deviation
- Time frame
- Through study completion, an average of 6.09 weeks.
What was measured
Duration of treatment is defined as the last dose date minus the first dose date of the dose cohort plus 1 expressed in weeks.
Groups in this outcome
MRZ 0.5 mg/m^2
Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
| Group | Source count |
|---|---|
| MRZ 0.5 mg/m^2 | 15 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| MRZ 0.5 mg/m^2 | 6.09 | 4.661 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 4.661
- value
- 6.09
- denoms
- counts
- group Id
- OG000
- value
- 15
- units
- Participants
- description
- Duration of treatment is defined as the last dose date minus the first dose date of the dose cohort plus 1 expressed in weeks.
- dispersion Type
- Standard Deviation
- groups
- description
- Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
- id
- OG000
- title
- MRZ 0.5 mg/m^2
- param Type
- MEAN
- reporting Status
- POSTED
- time Frame
- Through study completion, an average of 6.09 weeks.
- title
- Duration of MRZ Treatment
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle